LONG-TERM TREATMENT WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): POOLED SAFETY AND EFFICACY WITH OVER 4 YEARS' TREATMENT

被引：0
|
作者：
van Hoogstraten, Hubert [1 ]
St John, Gregory [2 ]
Thangavelu, Karthinathan [3 ]
Jose Gomez-Reino, Juan [4 ]
Antonio Maldonado-Cocco, Jose [5 ]
Carlos Salazar, Juan [6 ]
Huizinga, Thomas [7 ]
Wilson, Elaine [8 ]
Burmester, Gerd R. [9 ]
机构：
[1] Sanofi Genzyme, Global Med Affairs, Bridgewater, NJ USA
[2] Regeneron Pharmaceut Inc, Med Affairs, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] Sanofi Genzyme, Biostat, Bridgewater, NJ USA
[4] Complejo Hosp Univ Santiago Compostela, Rheumatol, Santiago, Spain
[5] Buenos Aires Univ, Sch Med, Buenos Aires, DF, Argentina
[6] Riesgo Fractura SA CAYRE, Rheumatol, Bogota, Colombia
[7] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands
[8] Sanofi Genzyme, Rheumatol, Oxford, England
[9] Charite Univ Med Berlin, Rheumatol & Clin Immunol, Berlin, Germany
来源：
RHEUMATOLOGY | 2019年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
080
引用
收藏
页码：74 / 75
页数：2
相关论文
共 50 条
  • [41] A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs
    Klareskog, L.
    Gaubitz, M.
    Rodriguez-Valverde, V.
    Malaise, M.
    Dougados, M.
    Wajdula, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) : 1578 - 1584
  • [42] Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial
    Rantalaiho, Vappu
    Sandstrom, Tia
    Koski, Juhani
    Hannonen, Pekka
    Mottonen, Timo
    Kaipiainen-Seppanen, Oili
    Yli-Kerttula, Timo
    Kauppi, Markku J.
    Uutela, Toini
    Malmi, Timo
    Julkunen, Heikki
    Laasonen, Leena
    Kautiainen, Hannu
    Leirisalo-Repo, Marjatta
    [J]. ARTHRITIS CARE & RESEARCH, 2019, 71 (11) : 1450 - 1458
  • [43] THE LONG-TERM PREDICTORS OF FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS
    Oliveira, D. Santos
    Martins, A.
    Samoes, B.
    Martins, F. R.
    Pinheiro, F. Oliveira
    Rato, M.
    Nicolau, R.
    Vaz, C.
    Bernardes, M.
    Costa, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1224 - 1225
  • [44] Effects of Long-Term Disease-Modifying Antirheumatic Drugs on Endothelial Function in Patients with Early Rheumatoid Arthritis
    Turiel, M.
    Tomasoni, L.
    Sitia, S.
    Cicala, S.
    Gianturco, L.
    Ricci, C.
    Atzeni, F.
    Colonna, V. De Gennaro
    Longhi, M.
    Sarzi-Puttini, P.
    [J]. CARDIOVASCULAR THERAPEUTICS, 2010, 28 (05) : e53 - e64
  • [45] Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study
    Terabe, Kenya
    Takahashi, Nobunori
    Asai, Shuji
    Hirano, Yuji
    Kanayama, Yasuhide
    Yabe, Yuichiro
    Oguchi, Takeshi
    Fujibayashi, Takayoshi
    Ishikawa, Hisato
    Hanabayashi, Masahiro
    Hattori, Yosuke
    Suzuki, Mochihito
    Kishimoto, Kenji
    Ohashi, Yoshifumi
    Imaizumi, Takahiro
    Imagama, Shiro
    Kojima, Toshihisa
    [J]. MODERN RHEUMATOLOGY, 2023, 33 (05) : 891 - 898
  • [46] Etanercept in combination with conventional disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to methotrexate
    Koyama, Yoshinobu
    Shiraishi, Hirokazu
    Ohta, Toshiyuki
    Uchino, Ayumi
    [J]. MODERN RHEUMATOLOGY, 2012, 22 (01) : 100 - 108
  • [47] Long-Term Treatment with Antithyroid Drugs: Efficacy and Safety
    Malboosbaf, Ramin
    Azizi, Fereidoun
    [J]. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2020, 18
  • [48] COST-EFFECTIVENESS OF BIOLOGICS COMPARED TO CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS IN FINLAND
    Joensuu, J. T.
    Aaltonen, K. J.
    Aronen, P.
    Sokka, T.
    Puolakka, K.
    Tuompo, R.
    Korpela, M.
    Vasala, M.
    Ilva, K.
    Nordstrom, D.
    Blom, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A648 - A648
  • [49] Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology
    Barth, Kaia
    Gill, Harsimrat
    Singh, Namrata
    [J]. CURRENT OPINION IN RHEUMATOLOGY, 2024, 36 (02) : 113 - 119
  • [50] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    van Vollenhoven, R. F.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 40 - 41
12345